碘-125 种子近距离放疗联合抗 PD-1 抗体在肺癌治疗中的临床应用。
Clinical Application of Iodine-125 Seed Brachytherapy Combined with Anti-PD-1 Antibodies in the Treatment of Lung Cancer.
机构信息
Department of Oncology, Hebei General Hospital, Shijiazhuang, China.
Department of Oncology, Hebei General Hospital, Shijiazhuang, China; North China University of Science and Technology, Tang shan, China.
出版信息
Clin Ther. 2020 Aug;42(8):1612-1616. doi: 10.1016/j.clinthera.2020.05.018. Epub 2020 Jul 7.
PURPOSE
The purpose of this case report was to investigate the clinical efficacy and tolerability of anti-programmed cell death protein (PD)-1 antibody combined with iodine (I)-125 seed brachytherapy in lung cancer treatment.
METHODS
Three patients with advanced PD-L1-positive non-small-cell lung cancer were treated first with I-125 seed brachytherapy and then with anti-PD-1 antibody. Clinical efficacy was evaluated with Response Evaluation Criteria in Solid Tumors.
FINDINGS
All 3 patients had complete response or partial response. None of the 3 patients had reported obvious adverse events.
IMPLICATIONS
Encouraging preliminary results provide important support for further clinical treatment of lung cancer using anti-PD-1 antibody combined with I-125 seed brachytherapy.
目的
本病例报告旨在探讨抗程序性死亡蛋白（PD）-1 抗体联合碘（I）-125 种子近距离放疗治疗肺癌的临床疗效和耐受性。
方法
对 3 例晚期 PD-L1 阳性非小细胞肺癌患者首先采用 I-125 种子近距离放疗，然后采用抗 PD-1 抗体治疗。采用实体瘤反应评价标准评价临床疗效。
结果
3 例患者均达到完全缓解或部分缓解。3 例患者均未报告明显不良反应。
结论
令人鼓舞的初步结果为进一步采用抗 PD-1 抗体联合 I-125 种子近距离放疗治疗肺癌提供了重要的临床治疗支持。
Zotero 插件